Trials of a new Coronavirus vaccine

This week, human trials of a new coronavirus vaccine developed by researchers at Imperial College London, backed by government funding, will commence; the next significant milestone in our efforts to develop a vaccine to provide protection against coronavirus to people in the UK and around the world.

The Coronavirus pandemic has had a huge impact on daily life. In the long-term, a viable vaccine could be vital for protecting the most vulnerable and helping people to get back to normal life.   The government has backed Imperial College London's research with over £40 million, and it is now one of the world’s front running efforts, underlining the ingenuity of British researchers. If human trials are successful a vaccine will not only help us tackle coronavirus but also emerging diseases now and into the future.   By backing Imperial College London and their alternative vaccine platform, we have enhanced the UK’s vaccine portfolio, increasing our chances of identifying a successful vaccine that will help us to control the virus and save lives.